1 gen 2007 anni - Food and Drug Administration Amendments Act of 2007

Descrizione:

Specifically authorized FDA to require manufacturers post-marketing clinical studies to monitor for risks infected during the pre-market approval process
Also required REMS programs where necessary. What is a REMS program?

Aggiunto al nastro di tempo:

Data: